ifosfamide has been researched along with Breast Cancer in 158 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The feasibility of the docetaxel-ifosfamide combination, as well as the definition of maximum tolerated doses (MTD) in a previous phase I study, led us to continue evaluating the regimen in an extended phase II study in patients with HER2-non-overexpressing, anthracycline pre-treated advanced breast cancer." | 9.12 | Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines. ( Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Tsakonas, G; Tsavaris, N, 2007) |
| "The established clinical activity of docetaxel and ifosfamide as single agents in anthracycline pre-treated breast cancer, led us to conduct a phase I-II study to define the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and clinical activity of the docetaxel+ifosfamide combination in this setting." | 9.12 | Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study. ( Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Skopelitis, H; Tsakonas, G; Tsavaris, N, 2007) |
| "Given the established individual activity of docetaxel and ifosfamide in anthracycline pretreated advanced breast cancer, the present phase I-II study aimed to define the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), and activity of the docetaxel-ifosfamide combination in this setting." | 9.10 | Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. ( Gregoriou, A; Kosmas, C; Malamos, N; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N, 2003) |
| "The purpose of this randomized phase III trial was to study whether medroxyprogesterone acetate (MPA) maintenance treatment prolongs the time to progression in advanced breast cancer patients responding to an induction chemotherapy." | 9.09 | Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group. ( Becher, R; Bechtel, C; Berke, A; Borquez, D; Donsbach, GM; Hartwich, G; Hawig, I; Heckmann, M; Hirche, H; Huhn, R; Klaassen, U; Kloke, O; Oberhoff, C; Rudolph, R; Schindler, AE; Schnepper, U; Seeber, S; Stephan, L; Szanto, J; Wolf, E, 1999) |
| "A prospective trial to evaluate the efficacy and toxicity of ifosfamide (IFX) and vinorelbine (VNB) in patients with prior anthracycline therapy for metastatic breast cancer (MBC) was conducted." | 9.09 | Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. ( Aziz, Z; Qazi, S; Rehman, A, 1999) |
| "Forty-six patients were included in a phase II study to evaluate the response rate and toxicity of a combination of ifosfamide and vinorelbine in metastatic breast cancer patients previously treated with one or more regimens of chemotherapy." | 9.09 | Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. ( Albistur, JJ; Barnadas, A; Constenla, M; Estévez, LG; Frau, A; Lizón, J; Lobo, F; Martínez, P; Méndez, M; Provencio, M; Sánchez, MJ, 1999) |
| "A Phase 1 trial was conducted in patients with estrogen negative receptors (ER) or hormone refractory metastatic breast cancer to determine the maximum tolerated dose (MTD) of ifosfamide with a fixed dose of doxorubicin." | 9.09 | Phase 1 trial of ifosfamide and adriamycin in metastatic breast cancer. ( Akram, M; Aziz, Z; Ilyas, N; Sana, S, 2001) |
| "Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim)." | 9.08 | The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. ( Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D, 1995) |
| "We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer." | 9.08 | Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. ( Elfenbein, GJ; Fields, KK; Perkins, JB, 1995) |
| "Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity." | 9.08 | Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. ( Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS, 1995) |
| "28 patients with recurrent advanced breast cancer were treated with a salvage regimen consisting of vincristine, epirubicin and ifosfamide/mesna (VIE)." | 9.08 | Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. ( Gurney, H; Harnett, P; Kefford, R; Stuart-Harris, R, 1995) |
| "In a randomized, phase II trial, we evaluated the effectiveness of continued chemotherapy with epirubicin/ ifosfamide versus unmaintained treatment interruption in advanced metastatic breast cancer." | 9.08 | Epirubicin and ifosfamide in metastatic breast cancer. ( Bartels, H; Becher, R; DeDycker, R; Fischedick, AR; Halabi, S; Hartwich, G; Hawig, I; Hayungs, J; Hering, KG; Hirche, H; Höfeler, H; Huhn, R; Illiger, HJ; Kloke, O; Ohl, S; Pielken, HJ; Rieche, K; Seeber, S; Szanto, J; Wolf, E, 1996) |
| "To evaluate the efficacy and toxicity of the combination of ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy in metastatic breast cancer (MBC)." | 9.08 | Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. ( Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1996) |
| "The new combination of ifosfamide and vinorelbine was evaluated in a phase II study of patients with metastatic breast cancer." | 9.08 | Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. ( Cafiero, F; Gipponi, M; Landucci, M; Pronzato, P; Queirolo, P; Vaira, F; Vigani, A, 1997) |
| "This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions." | 9.08 | Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997) |
| "The aim of this paper is to evaluate the activity of ifosfamide in previously treated patients with metastatic breast cancer." | 9.08 | Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. ( Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Valero, V; Walters, RS, 1998) |
| "We have recently treated 66 women with breast cancer with escalating doses of ifosfamide, carboplatin, and etoposide (ICE) followed by autologous stem cell rescue (ASCR)." | 9.07 | Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients. ( Elfenbein, GJ; Fields, KK; Hiemenz, JW; Janssen, WE; Kronish, LE; Machak, MC; Perkins, JP; Zorsky, PE, 1993) |
| "Ifosfamide has single agent activity in advanced breast cancer and may potentiate the activity of doxorubicin." | 9.07 | Results of chemotherapy using ifosfamide with doxorubicin in advanced breast cancer. ( Cantwell, B; Gumbrell, L; Lennard, T; Lind, M; Millward, M; Robinson, A, 1994) |
| "A phase II trial was performed to evaluate the efficacy and toxicity of a combination of ifosfamide (IFX) and mitoxantrone (MXN) as first-line chemotherapy for metastatic breast carcinoma." | 9.07 | Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer. ( Bianco, A; Cuevas, MA; Lacava, JA; Leone, BA; Machiavelli, M; Perez, JE; Rabinovich, MG; Rodriguez, R; Romero, A; Vallejo, CT, 1993) |
| "A combination of 5-fluorouracil (5-FU), adriamycin, and cyclophosphamide (FAC) was compared to a combination of 5-FU, adriamycin, and ifosfamide (FAI) in the treatment of metastatic breast cancer." | 9.04 | Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Hersh, EM; Hortobagyi, GN; Legha, SS; Tashima, CK; Yap, HY, 1979) |
| "Ifosfamide is an alkylating agent active in various tumor types including breast cancer." | 8.82 | Ifosfamide in advanced/disseminated breast cancer. ( La Mura, N; Lombardi, D; Sorio, R; Spazzapan, S; Tabaro, G; Veronesi, A, 2003) |
| "Ifosfamide is an alkylating agent that has clearly demonstrated efficacy against advanced breast cancer." | 8.78 | Activity of ifosfamide in breast cancer. ( Hortobagyi, GN, 1992) |
| "The efficacy of platinum- and ifosfamide-based chemotherapy regimens as salvage treatment in metastatic breast cancer (MBC) has not yet been sufficiently evaluated." | 7.81 | Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer. ( Eucker, J; Habbel, P; Kaul, D; Kurreck, A; Neumann, C; Possinger, K; Regierer, AC; Scholz, CW; Schulz, CO, 2015) |
| "We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC)." | 7.76 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. ( Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH, 2010) |
| "To observe the efficacy of navelbine combined with ifosfamide and cisplatin in the treatment of advanced breast cancer." | 7.72 | [Clinical observation of the efficacy of navelbine combined with ifosfamide and cisplatin in the treatment of advanced breast cancer]. ( Luo, RC; You, CX; Zheng, H, 2003) |
| "Thirty-one patients with advanced breast cancer either resistant to anthracycline-based regimens or relapsing after anthracycline-based adjuvant chemotherapy received a combination of a 3-h infusion of paclitaxel 135 mg/m2 on day 1 and a 4-h infusion of ifosfamide 1." | 7.71 | Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer. ( Blomqvist, C; Elomaa, L; Järvenpää, R; Kellokumpu-Lehtinen, P; Kokko, R; Lantto, A; Lehtinen, R, 2002) |
| "We report three cases of women with breast cancer who developed renal impairment following treatment with high-dose ifosfamide." | 7.70 | Tubulointerstitial nephritis following high-dose ifosfamide in three breast cancer patients. ( Hill, PA; Power, DA; Prince, HM, 2000) |
| "Ifosfamide (IFO) at a dose of 5 g/m2, was administered as a 24-h infusion to 15 patients with metastatic (12) or locally advanced (3) breast cancer (age range 33-59 years, median 46)." | 7.69 | Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. ( Boddy, AV; Idle, JR; Lind, MJ; Proctor, M; Simmonds, D, 1995) |
| "A total of 51 fully evaluable patients with advanced and intensively pretreated breast cancer were treated with a combination chemotherapy of ifosfamide plus mesna, methotrexate and 5-fluorouracil." | 7.68 | Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer. ( Becher, R; Höfeler, H; Kloke, O; May, D; Niederle, N; Richter, R; Scheulen, ME; Schmidt, CG; Wandl, U, 1991) |
| "Four courses of ifosfamide with mesna given by intravenous infusions were combined with bolus doxorubicin in a phase II trial to treat patients with breast cancer." | 7.68 | Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. ( Cantwell, BM; Harris, AL; Millward, MJ, 1990) |
| "In an ongoing phase II trial conducted in advanced breast cancer, we tested a therapy schedule consisting of continuous, 24-h infusion of 5 g/m2 ifosfamide (IFO) in 3 1 dextrose saline with mesna (MSN), repeated every 3 weeks until disease progression." | 7.68 | Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer. ( Beauduin, M; Closon, MT; Focan, C; Majois, F; Michel, J; Paridaens, R; Piccart, M; Salamon, E; Tueni, E; Vindevoghel, A, 1990) |
| "The object of the study was to evaluate the effectiveness of ifosfamide/etoposide and mesna therapy in advanced breast cancer." | 7.68 | Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer. ( Bickel, J; Drings, P; Kaufmann, M; Manegold, C; Schmid, H; Worst, P, 1990) |
| "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide." | 7.68 | Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function. ( Paridaens, R; Piccart, M; Richard, V; Sculier, JP, 1990) |
| "The combination of ifosfamide (IFO) and epirubicin (EPI) has been found to be an effective regimen in the treatment of metastatic tumours and shows remarkable activity in heavily pretreated breast cancer patients." | 7.68 | Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. ( Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B, 1990) |
| "Ifosfamide has definite efficacy in many malignant tumours, including breast cancer." | 7.68 | Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer. ( el-Khodari, A; Elserafi, M; Gad-el-Mawla, N; Gafaar, R; Hamza, MR; Khaled, H; Zikri, ZK, 1990) |
| "Twenty-six cycles of high-dose ifosfamide + mesna (HD-IFO + M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks." | 7.67 | Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer. ( Brade, WP; Dittrich, C; Herold, C; Keller, A; Mader, R; Moser, K; Schlappack, O; Steger, GG, 1988) |
| "Ninety patients with advanced breast cancer received a polychemotherapeutic program composed of 5-fluorouracil, cyclophosphamide, and prednisone with or without vincristine as a control group in a series of four consecutive Phase II clinical trials of new drug programs." | 7.65 | An analysis of a multiple-drug program in the treatment of patients with advanced breast cancer utilizing 5-fluorouracil, cyclophosphamide, and prednisone with or without vincristine. ( Ahmann, DL; Bisel, HF; Eagan, RT; Edmonson, JH; Hahn, RG; Steinfeld, JL; Taylor, WF; Tormey, DC, 1975) |
| " Ifosfamide with G-CSF in combination with doxorubicin or paclitaxel achieves effective mobilization of PBPC and anti-tumor activity with minimal toxicity." | 6.69 | Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. ( Brettell, M; Briggs, P; Chapple, P; Francis, P; Gardyn, J; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Toner, GC; Wolf, M, 1999) |
| "Twenty-five patients with metastatic breast cancer were treated with ICE after failure of previous chemotherapy." | 6.69 | Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. ( Asbury, R; Boros, L; Chang, AY; Garrow, G; Hui, L; Rubins, J, 1999) |
| "Eighteen women with stage IV breast cancer were enrolled in a Phase I study of an escalating dose of ifosfamide (1." | 6.68 | A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. ( Bitran, JD; Gambino, A; Marsik, S; Samuels, BL; White, L, 1995) |
| "Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue." | 6.67 | Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993) |
| "Ifosfamide is an alkylating agent that has demonstrated efficacy in the treatment of several malignancies." | 6.39 | Ifosfamide in the treatment of breast cancer. ( Overmoyer, BA, 1996) |
| "Doxorubicin, the most active agent for breast cancer, was studied first." | 6.39 | Paclitaxel combination therapy in the treatment of metastatic breast cancer. ( Holmes, FA, 1996) |
| "Metastases from cystosarcoma phyllodes are rare, and treatment generally is ineffective." | 6.38 | Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. ( Fisher, C; Hawkins, RE; McKinna, JA; Schofield, JB; Wiltshaw, E, 1992) |
| "In conclusion, ifosfamide's efficacy in breast cancer has been confirmed and the drug is highly recommended in combination chemotherapy as a first-line treatment." | 6.38 | Use of ifosfamide in the management of breast cancer. ( Gad-el-Mawla, N, 1992) |
| "Although breast cancer is, unfortunately, not uncommon in women, a mere 0." | 5.39 | High-dose tamoxifen plus ifosfamide and anthracycline in a patient with angiosarcoma of the breast. ( Chang, YC; Hsiao, CH; Tsai, CC; Yeh, KH, 2013) |
| "Breast stromal sarcoma is very rare, accounting for less than 1% of mammary neoplasms, and the treatment strategy is not well established, especially regarding chemotherapy." | 5.37 | Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case. ( Inoue, K; Iwase, H; Kuriwaki, K; Sueta, A; Yamamoto, Y, 2011) |
| "Ifosfamide is a prodrug that requires bioactivation by cytochrome P450 for antitumour activity." | 5.32 | CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. ( Baumann, F; Brauckhoff, M; Horn, LC; Knüpfer, H; Köhler, U; Preiss, R; Schmidt, R; Schönfelder, M, 2004) |
| "Local control rate for inflammatory breast cancer (IBC) is < 50% with standard chemotherapy-radiotherapy regimen." | 5.30 | Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin. ( Boyages, J; Gurney, H; Harnett, P; Kefford, R, 1998) |
| "The model systems were human breast carcinoma (MX1/3) and human sarcoma (S117) grown in nude mice." | 5.28 | Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice. ( Biersack, A; Roszinski, S; Wagner, T; Weiss, C; Wiedemann, G, 1992) |
| "Thirty-two patients with metastatic breast cancer had previously been treated with chemotherapy (including anthracyclines)." | 5.28 | High-dose ifosfamide and mesna in advanced breast cancer. A phase II study. ( Milla, A; Sanchiz, F, 1990) |
| "Chemotherapy for liver metastasis of breast cancer has rarely been found effective." | 5.28 | [Clinical efficacy of ifosfamide for liver metastasis of breast cancer]. ( Ando, K; Funahashi, H; Imai, T; Kato, M; Kato, N; Narita, T; Odaka, K; Oike, E; Ono, M; Sato, Y, 1990) |
| "Patients with metastatic breast cancer entered the study after hormone therapy had failed; prior treatment with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) was also allowed." | 5.28 | A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer. ( Hossfeld, DK; Jonat, W; Langenbuch, T; Mross, K, 1990) |
| "The feasibility of the docetaxel-ifosfamide combination, as well as the definition of maximum tolerated doses (MTD) in a previous phase I study, led us to continue evaluating the regimen in an extended phase II study in patients with HER2-non-overexpressing, anthracycline pre-treated advanced breast cancer." | 5.12 | Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines. ( Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Tsakonas, G; Tsavaris, N, 2007) |
| "The established clinical activity of docetaxel and ifosfamide as single agents in anthracycline pre-treated breast cancer, led us to conduct a phase I-II study to define the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and clinical activity of the docetaxel+ifosfamide combination in this setting." | 5.12 | Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study. ( Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Skopelitis, H; Tsakonas, G; Tsavaris, N, 2007) |
| "Given the established individual activity of docetaxel and ifosfamide in anthracycline pretreated advanced breast cancer, the present phase I-II study aimed to define the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), and activity of the docetaxel-ifosfamide combination in this setting." | 5.10 | Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. ( Gregoriou, A; Kosmas, C; Malamos, N; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N, 2003) |
| "The purpose of this randomized phase III trial was to study whether medroxyprogesterone acetate (MPA) maintenance treatment prolongs the time to progression in advanced breast cancer patients responding to an induction chemotherapy." | 5.09 | Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group. ( Becher, R; Bechtel, C; Berke, A; Borquez, D; Donsbach, GM; Hartwich, G; Hawig, I; Heckmann, M; Hirche, H; Huhn, R; Klaassen, U; Kloke, O; Oberhoff, C; Rudolph, R; Schindler, AE; Schnepper, U; Seeber, S; Stephan, L; Szanto, J; Wolf, E, 1999) |
| "A prospective trial to evaluate the efficacy and toxicity of ifosfamide (IFX) and vinorelbine (VNB) in patients with prior anthracycline therapy for metastatic breast cancer (MBC) was conducted." | 5.09 | Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. ( Aziz, Z; Qazi, S; Rehman, A, 1999) |
| "Forty-six patients were included in a phase II study to evaluate the response rate and toxicity of a combination of ifosfamide and vinorelbine in metastatic breast cancer patients previously treated with one or more regimens of chemotherapy." | 5.09 | Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. ( Albistur, JJ; Barnadas, A; Constenla, M; Estévez, LG; Frau, A; Lizón, J; Lobo, F; Martínez, P; Méndez, M; Provencio, M; Sánchez, MJ, 1999) |
| "The aim of the study was to investigate a dose-intensified, preoperative chemotherapy with 3 cycles (cy) of epirubicin 60 mg/m2, ifosfamide 5 g/m2 with mesna 5 g/m2, biweekly with G-CSF 5 micrograms/kg (filgrastim), in terms of toxicity, clinical and pathological remission rates and changes of immunohistochemical characteristics (ER, PR, c-erbB2, p53) during chemotherapy of inoperable patients (pt) with poor prognosis (locally advanced (LABC, 9 pt), inflammatory breast cancer (IBC, 12 pt) and M0." | 5.09 | Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission. ( Blohmer, JU; Elling, D; Fleige, B; Grineisen, Y; Kissner, L; Lichtenegger, W; Paepke, S, 1999) |
| "A Phase 1 trial was conducted in patients with estrogen negative receptors (ER) or hormone refractory metastatic breast cancer to determine the maximum tolerated dose (MTD) of ifosfamide with a fixed dose of doxorubicin." | 5.09 | Phase 1 trial of ifosfamide and adriamycin in metastatic breast cancer. ( Akram, M; Aziz, Z; Ilyas, N; Sana, S, 2001) |
| "Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim)." | 5.08 | The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. ( Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D, 1995) |
| "We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer." | 5.08 | Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. ( Elfenbein, GJ; Fields, KK; Perkins, JB, 1995) |
| "Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity." | 5.08 | Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. ( Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS, 1995) |
| "28 patients with recurrent advanced breast cancer were treated with a salvage regimen consisting of vincristine, epirubicin and ifosfamide/mesna (VIE)." | 5.08 | Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. ( Gurney, H; Harnett, P; Kefford, R; Stuart-Harris, R, 1995) |
| "In a randomized, phase II trial, we evaluated the effectiveness of continued chemotherapy with epirubicin/ ifosfamide versus unmaintained treatment interruption in advanced metastatic breast cancer." | 5.08 | Epirubicin and ifosfamide in metastatic breast cancer. ( Bartels, H; Becher, R; DeDycker, R; Fischedick, AR; Halabi, S; Hartwich, G; Hawig, I; Hayungs, J; Hering, KG; Hirche, H; Höfeler, H; Huhn, R; Illiger, HJ; Kloke, O; Ohl, S; Pielken, HJ; Rieche, K; Seeber, S; Szanto, J; Wolf, E, 1996) |
| "To evaluate the efficacy and toxicity of the combination of ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy in metastatic breast cancer (MBC)." | 5.08 | Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. ( Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1996) |
| "The new combination of ifosfamide and vinorelbine was evaluated in a phase II study of patients with metastatic breast cancer." | 5.08 | Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. ( Cafiero, F; Gipponi, M; Landucci, M; Pronzato, P; Queirolo, P; Vaira, F; Vigani, A, 1997) |
| "This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions." | 5.08 | Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997) |
| "The aim of this paper is to evaluate the activity of ifosfamide in previously treated patients with metastatic breast cancer." | 5.08 | Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. ( Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Valero, V; Walters, RS, 1998) |
| "We have recently treated 66 women with breast cancer with escalating doses of ifosfamide, carboplatin, and etoposide (ICE) followed by autologous stem cell rescue (ASCR)." | 5.07 | Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients. ( Elfenbein, GJ; Fields, KK; Hiemenz, JW; Janssen, WE; Kronish, LE; Machak, MC; Perkins, JP; Zorsky, PE, 1993) |
| "Ifosfamide has single agent activity in advanced breast cancer and may potentiate the activity of doxorubicin." | 5.07 | Results of chemotherapy using ifosfamide with doxorubicin in advanced breast cancer. ( Cantwell, B; Gumbrell, L; Lennard, T; Lind, M; Millward, M; Robinson, A, 1994) |
| "High-dose ifosfamide is associated with severe but usually reversible myocardial depression and malignant arrhythmias." | 5.07 | High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. ( Bryant, G; Cunnion, RE; Ognibene, FP; Parker, MM; Quezado, ZM; Reda, D; Wilson, WH, 1993) |
| "A phase II trial was performed to evaluate the efficacy and toxicity of a combination of ifosfamide (IFX) and mitoxantrone (MXN) as first-line chemotherapy for metastatic breast carcinoma." | 5.07 | Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer. ( Bianco, A; Cuevas, MA; Lacava, JA; Leone, BA; Machiavelli, M; Perez, JE; Rabinovich, MG; Rodriguez, R; Romero, A; Vallejo, CT, 1993) |
| "A combination of 5-fluorouracil (5-FU), adriamycin, and cyclophosphamide (FAC) was compared to a combination of 5-FU, adriamycin, and ifosfamide (FAI) in the treatment of metastatic breast cancer." | 5.04 | Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Hersh, EM; Hortobagyi, GN; Legha, SS; Tashima, CK; Yap, HY, 1979) |
| "Ifosfamide is an alkylating agent active in various tumor types including breast cancer." | 4.82 | Ifosfamide in advanced/disseminated breast cancer. ( La Mura, N; Lombardi, D; Sorio, R; Spazzapan, S; Tabaro, G; Veronesi, A, 2003) |
| "Ifosfamide is an alkylating agent that has clearly demonstrated efficacy against advanced breast cancer." | 4.78 | Activity of ifosfamide in breast cancer. ( Hortobagyi, GN, 1992) |
| "The alkylating agent ifosfamide, an analog of cyclophosphamide, has demonstrated significant activity in soft tissue sarcoma and testicular carcinoma." | 4.77 | Ifosfamide. ( Baker, LH; Zalupski, M, 1988) |
| "The efficacy of platinum- and ifosfamide-based chemotherapy regimens as salvage treatment in metastatic breast cancer (MBC) has not yet been sufficiently evaluated." | 3.81 | Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer. ( Eucker, J; Habbel, P; Kaul, D; Kurreck, A; Neumann, C; Possinger, K; Regierer, AC; Scholz, CW; Schulz, CO, 2015) |
| "We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC)." | 3.76 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. ( Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH, 2010) |
| "To observe the efficacy of navelbine combined with ifosfamide and cisplatin in the treatment of advanced breast cancer." | 3.72 | [Clinical observation of the efficacy of navelbine combined with ifosfamide and cisplatin in the treatment of advanced breast cancer]. ( Luo, RC; You, CX; Zheng, H, 2003) |
| "Thirty-one patients with advanced breast cancer either resistant to anthracycline-based regimens or relapsing after anthracycline-based adjuvant chemotherapy received a combination of a 3-h infusion of paclitaxel 135 mg/m2 on day 1 and a 4-h infusion of ifosfamide 1." | 3.71 | Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer. ( Blomqvist, C; Elomaa, L; Järvenpää, R; Kellokumpu-Lehtinen, P; Kokko, R; Lantto, A; Lehtinen, R, 2002) |
| "In three new approved indications (non Hodgkin's lymphoma, Hodgkin's lymphoma and acute lymphoblastic leukaemia) and in three previously existing indications (ovarian cancer, soft tissue sarcomas and osteogenic sarcomas), non comparative trials show that ifosfamide can induce tumour regression in patients who relapse after a first course of chemotherapy (sometimes containing cyclophosphamide)." | 3.70 | Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness. ( , 1998) |
| "Vinorelbine and ifosfamide are active drugs against breast cancer, but the best treatment schedule has yet to be defined by preclinical or clinical studies." | 3.70 | Combined 4-hydroxy-ifosfamide and vinorelbine treatment in established and primary human breast cell cultures. ( Amadori, D; Barzanti, F; Frassineti, GL; Gasperi-Campani, A; Ricotti, L; Tesei, A; Zoli, W, 2000) |
| "We report three cases of women with breast cancer who developed renal impairment following treatment with high-dose ifosfamide." | 3.70 | Tubulointerstitial nephritis following high-dose ifosfamide in three breast cancer patients. ( Hill, PA; Power, DA; Prince, HM, 2000) |
| "Ifosfamide (IFO) at a dose of 5 g/m2, was administered as a 24-h infusion to 15 patients with metastatic (12) or locally advanced (3) breast cancer (age range 33-59 years, median 46)." | 3.69 | Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. ( Boddy, AV; Idle, JR; Lind, MJ; Proctor, M; Simmonds, D, 1995) |
| "In MX1 human breast cancer xenografts grown on the hind paw of thymusaplastic nude mice the effect of ifosfamide on tumor oxygenation, tumor pH and the concentration of lactic acid have been determined at mean tumor temperatures of 32 degrees C, 37 degrees C and 41 degrees C." | 3.69 | The effect of ifosfamide on tumor oxygenation at different temperatures. ( Mendoza, AS; Mentzel, M; Wiedemann, G, 1994) |
| "High-dose ifosfamide (HD-IFX) has shown significant antitumor activity in advanced sarcoma and breast carcinoma." | 3.69 | Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. ( Albanell, J; Baselga, J; Bellmunt, J; Casado, S; Eres, N; Ribas, A, 1997) |
| "A total of 51 fully evaluable patients with advanced and intensively pretreated breast cancer were treated with a combination chemotherapy of ifosfamide plus mesna, methotrexate and 5-fluorouracil." | 3.68 | Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer. ( Becher, R; Höfeler, H; Kloke, O; May, D; Niederle, N; Richter, R; Scheulen, ME; Schmidt, CG; Wandl, U, 1991) |
| "Four courses of ifosfamide with mesna given by intravenous infusions were combined with bolus doxorubicin in a phase II trial to treat patients with breast cancer." | 3.68 | Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. ( Cantwell, BM; Harris, AL; Millward, MJ, 1990) |
| "In an ongoing phase II trial conducted in advanced breast cancer, we tested a therapy schedule consisting of continuous, 24-h infusion of 5 g/m2 ifosfamide (IFO) in 3 1 dextrose saline with mesna (MSN), repeated every 3 weeks until disease progression." | 3.68 | Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer. ( Beauduin, M; Closon, MT; Focan, C; Majois, F; Michel, J; Paridaens, R; Piccart, M; Salamon, E; Tueni, E; Vindevoghel, A, 1990) |
| "The object of the study was to evaluate the effectiveness of ifosfamide/etoposide and mesna therapy in advanced breast cancer." | 3.68 | Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer. ( Bickel, J; Drings, P; Kaufmann, M; Manegold, C; Schmid, H; Worst, P, 1990) |
| "A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide." | 3.68 | Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function. ( Paridaens, R; Piccart, M; Richard, V; Sculier, JP, 1990) |
| "The combination of ifosfamide (IFO) and epirubicin (EPI) has been found to be an effective regimen in the treatment of metastatic tumours and shows remarkable activity in heavily pretreated breast cancer patients." | 3.68 | Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. ( Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B, 1990) |
| "Ifosfamide has definite efficacy in many malignant tumours, including breast cancer." | 3.68 | Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer. ( el-Khodari, A; Elserafi, M; Gad-el-Mawla, N; Gafaar, R; Hamza, MR; Khaled, H; Zikri, ZK, 1990) |
| "Twenty-six cycles of high-dose ifosfamide + mesna (HD-IFO + M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks." | 3.67 | Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer. ( Brade, WP; Dittrich, C; Herold, C; Keller, A; Mader, R; Moser, K; Schlappack, O; Steger, GG, 1988) |
| "Ninety patients with advanced breast cancer received a polychemotherapeutic program composed of 5-fluorouracil, cyclophosphamide, and prednisone with or without vincristine as a control group in a series of four consecutive Phase II clinical trials of new drug programs." | 3.65 | An analysis of a multiple-drug program in the treatment of patients with advanced breast cancer utilizing 5-fluorouracil, cyclophosphamide, and prednisone with or without vincristine. ( Ahmann, DL; Bisel, HF; Eagan, RT; Edmonson, JH; Hahn, RG; Steinfeld, JL; Taylor, WF; Tormey, DC, 1975) |
| "In patients with recurrent breast cancer, triple-modality therapy is feasible with acceptable toxicity." | 2.70 | Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease. ( Feyerabend, T; Jäger, B; Mahlmann, B; Richter, E; Vesely, H; Wiedemann, GJ, 2001) |
| "Paclitaxel was given after the first dose of ifosfamide on Day 1." | 2.69 | A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. ( Berkowitz, R; Bunnell, CA; Buswell, L; Muto, M; Sheets, E; Shulman, LN; Thompson, L, 1998) |
| " Ifosfamide with G-CSF in combination with doxorubicin or paclitaxel achieves effective mobilization of PBPC and anti-tumor activity with minimal toxicity." | 2.69 | Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. ( Brettell, M; Briggs, P; Chapple, P; Francis, P; Gardyn, J; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Toner, GC; Wolf, M, 1999) |
| "Twenty-five patients with metastatic breast cancer were treated with ICE after failure of previous chemotherapy." | 2.69 | Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. ( Asbury, R; Boros, L; Chang, AY; Garrow, G; Hui, L; Rubins, J, 1999) |
| "Tumor relapse occurring in high-risk breast cancer patients after high-dose chemotherapy (HDC) and autologous stem-cell transplantation may arise from cells resistant to chemotherapy, as well as from tumor cells reinfused with autologous stem cell grafts." | 2.69 | Combination of high-dose chemotherapy and monoclonal antibody in breast-cancer patients: a pilot trial to monitor treatment effects on disseminated tumor cells. ( Behr, W; Brockmeyer, C; Ehnle, S; Hempel, P; Müller, P; Oruzio, D; Riethmüller, R; Schlimok, G; Wochner, M, 2000) |
| "Twenty-five women with advanced breast carcinoma refractory to first-line chemotherapy entered a phase II trial to evaluate the efficacy of ifosfamide and carboplatin." | 2.68 | Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma. ( Herman, RL; Kelley, AS; Muggia, FM; Russell, CA; Spicer, DV; Turrill, M, 1995) |
| "The ongoing phase I study reported here sought to determine the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin when given at specific times in combination with ifosfamide, mesna, and filgrastim." | 2.68 | Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. ( Palackdharry, CS, 1997) |
| "Eighteen women with stage IV breast cancer were enrolled in a Phase I study of an escalating dose of ifosfamide (1." | 2.68 | A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. ( Bitran, JD; Gambino, A; Marsik, S; Samuels, BL; White, L, 1995) |
| "Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue." | 2.67 | Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993) |
| " A daily dosage of 50 to 60 mg/kg ifosfamide on 5 consecutive days produced the best results." | 2.64 | Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. ( Brock, N; Burkert, H; Fichtner, E; Schnitker, J, 1976) |
| "Treatment for metaplastic breast carcinoma is relatively unknown because of the rarity of the disease, but studies suggest that removal of the tumor and adjuvant radiation therapy has the greatest benefit." | 2.52 | Metaplastic carcinoma of the breast. ( McKinnon, E; Xiao, P, 2015) |
| "While most invasive primary breast cancers are epithelial derived adenocarcinomas, rare neoplasms such as the phyllodes tumor may arise from mesenchymal tissue." | 2.49 | Unusual aggressive breast cancer: metastatic malignant phyllodes tumor. ( Singer, A; Tresley, J; Velazquez-Vega, J; Yepes, M, 2013) |
| "Formerly known as cystosarcoma phyllodes, the designation "phyllodes tumor" with appropriate qualification regarding malignant potential based on pathologic features is now the agreed-upon term." | 2.41 | Phyllodes tumors of the breast. ( Badve, S; Khan, SA, 2001) |
| "Primary soft tissue sarcoma (STS) of the breast is a rare and heterogeneous disease." | 2.41 | Primary soft tissue sarcoma of the breast. ( Benjamin, RS; Trent II, JC; Valero, V, 2001) |
| "Ifosfamide is an alkylating agent that has demonstrated efficacy in the treatment of several malignancies." | 2.39 | Ifosfamide in the treatment of breast cancer. ( Overmoyer, BA, 1996) |
| "Doxorubicin, the most active agent for breast cancer, was studied first." | 2.39 | Paclitaxel combination therapy in the treatment of metastatic breast cancer. ( Holmes, FA, 1996) |
| "Metastases from cystosarcoma phyllodes are rare, and treatment generally is ineffective." | 2.38 | Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. ( Fisher, C; Hawkins, RE; McKinna, JA; Schofield, JB; Wiltshaw, E, 1992) |
| "In conclusion, ifosfamide's efficacy in breast cancer has been confirmed and the drug is highly recommended in combination chemotherapy as a first-line treatment." | 2.38 | Use of ifosfamide in the management of breast cancer. ( Gad-el-Mawla, N, 1992) |
| "Malignant phyllodes tumors are rare breast neoplasms that are associated with a 6." | 1.51 | Complete remission of giant malignant phyllodes tumor with lung metastasis: A case report. ( Jung, JH; Kim, WW; Lee, J; Lee, JW; Lee, SJ; Moon, SH; Park, HY, 2019) |
| "Patients with bones or brain metastases were treated with palliative radiotherapy only or combined with Doxorubicin." | 1.43 | Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast. ( Blecharz, P; Jakubowicz, J; Kulpa, J; Mituś, JW; Reinfuss, M; Walasek, T, 2016) |
| " The novel dosing strategy for cyclophosphamide described herein is readily translatable to standard clinical regimens, represents a potentially significant advance in addressing the drug delivery challenge, and may have broad applicability for nanomedicines." | 1.42 | Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302). ( De Souza, R; Dumont, N; Espelin, CW; Gaddy, DF; Geretti, E; Hendriks, BS; Jaffray, DA; Lee, H; Leonard, SC; Moyo, V; Nielsen, UB; Wickham, TJ; Zheng, J, 2015) |
| "Premenopausal patients with breast cancer and more than 10 positive axillary nodes (BC>10) have a poor prognosis: In these patients the best adjuvant therapy (CT) has not yet been established." | 1.42 | Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer. ( Bratta, M; Candeloro, G; D'Orazi, V; Fumagalli, LA; Pasta, V; Rea, S; Recchia, F; Rosselli, M, 2015) |
| "Although breast cancer is, unfortunately, not uncommon in women, a mere 0." | 1.39 | High-dose tamoxifen plus ifosfamide and anthracycline in a patient with angiosarcoma of the breast. ( Chang, YC; Hsiao, CH; Tsai, CC; Yeh, KH, 2013) |
| "Breast stromal sarcoma is very rare, accounting for less than 1% of mammary neoplasms, and the treatment strategy is not well established, especially regarding chemotherapy." | 1.37 | Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case. ( Inoue, K; Iwase, H; Kuriwaki, K; Sueta, A; Yamamoto, Y, 2011) |
| "Pure primary squamous cell carcinoma (SCC) of the breast is rare and difficult to treat." | 1.35 | Primary squamous cell carcinoma of the breast: achieving long-term control with cisplatin-based chemotherapy. ( Bhatt, L; Fernando, I, 2009) |
| "Cystosarcoma phyllodes is an important but relatively uncommon fibroepithelial breast neoplasm that accounts for 0." | 1.35 | Metastatic phyllodes tumor causing small-bowel obstruction. ( Barrett, C; Kelly, RJ; McDermott, R; Swan, N, 2009) |
| "Orbital or sinus rhabdomyosarcoma is seen almost exclusively in the pediatric population, but may very rarely occur in adults." | 1.35 | Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer. ( Chesnutt, DA; Cummings, TJ; Heimann, A; Morris, CL; Mukundan, S, 2008) |
| "Ifosfamide is a prodrug that requires bioactivation by cytochrome P450 for antitumour activity." | 1.32 | CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. ( Baumann, F; Brauckhoff, M; Horn, LC; Knüpfer, H; Köhler, U; Preiss, R; Schmidt, R; Schönfelder, M, 2004) |
| "We studied 19 breast cancer (BC) patients and 17 multiple myeloma (MM) patients entered in a high-dose chemotherapy (HDC) program of tandem autografting with CD34+ cell-selected PBPC." | 1.32 | Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation. ( Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M, 2004) |
| "In the breast carcinoma cell line MCF7 glufosfamide inhibited both the synthesis of DNA and protein in a dose-dependent manner, as shown by the decreased incorporation of [3H-methyl]-thymidine into DNA and [14C]-methionine into protein of these cells." | 1.31 | Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent. ( Bertram, B; Bürkle, A; Kaina, B; Koepsell, H; Pohl, J; Seker, H; Wiesser, M, 2000) |
| "In patients with metastatic breast cancer (MBC), early dose intensification with multiple cycles of peripheral blood stem cell-supported high-dose chemotherapy (HDCT) seems superior to a late dose-intensification strategy." | 1.31 | Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. ( Bastert, G; Egerer, G; Goerner, R; Grischke, EM; Haas, R; Hensel, M; Ho, AD; Hohaus, S; Khbeis, T; Schneeweiss, A; Solomayer, E, 2001) |
| "LP from 13 breast cancer patients were analyzed." | 1.30 | Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. ( Bargou, R; Dörken, B; Hildebrandt, M; Körner, IJ; Krahl, D; Mapara, MY; Reichardt, P, 1997) |
| "Local control rate for inflammatory breast cancer (IBC) is < 50% with standard chemotherapy-radiotherapy regimen." | 1.30 | Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin. ( Boyages, J; Gurney, H; Harnett, P; Kefford, R, 1998) |
| "Twenty-six patients with breast cancer who had relapsed after previously receiving high-dose chemotherapy and autologous hematopoietic cell support received a second course of high-dose cytoreductive therapy and autologous hematopoietic cell support as salvage therapy." | 1.30 | High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. ( Bearman, S; Cagnoni, P; Jones, R; Nieto, Y; Peters, W; Ross, M; Shpall, E; Vredenburgh, J, 1999) |
| "Patients with metastatic breast cancer will receive 4-5 cycles of induction chemotherapy on one of the ongoing Medicine Branch protocols." | 1.29 | Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. ( Chiang, Y; Cowan, KH; Dunbar, CE; Goldspiel, B; Kohler, D; McDonagh, KT; Nienhuis, AW; O'Shaughnessy, JA; Sorrentino, BP; Wilson, W, 1994) |
| "In patients with breast cancer, especially metastatic breast cancer, undergoing HDCT and ABMT, the presence of K19 is associated with a poor prognosis." | 1.29 | Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. ( Elfenbein, GJ; Fields, KK; Janssen, WE; Moscinski, LC; Perkins, JB; Trudeau, WL, 1996) |
| "Paclitaxel was given at a dose of 120 mg/m2 to five patients, 135 mg/m2 to five patients, 150 mg/m2 to three patients, and 175 mg/m2 to 11 patients." | 1.29 | Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. ( Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L, 1996) |
| "The model systems were human breast carcinoma (MX1/3) and human sarcoma (S117) grown in nude mice." | 1.28 | Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice. ( Biersack, A; Roszinski, S; Wagner, T; Weiss, C; Wiedemann, G, 1992) |
| "Thirty-two patients with metastatic breast cancer had previously been treated with chemotherapy (including anthracyclines)." | 1.28 | High-dose ifosfamide and mesna in advanced breast cancer. A phase II study. ( Milla, A; Sanchiz, F, 1990) |
| "Chemotherapy for liver metastasis of breast cancer has rarely been found effective." | 1.28 | [Clinical efficacy of ifosfamide for liver metastasis of breast cancer]. ( Ando, K; Funahashi, H; Imai, T; Kato, M; Kato, N; Narita, T; Odaka, K; Oike, E; Ono, M; Sato, Y, 1990) |
| "Patients with metastatic breast cancer entered the study after hormone therapy had failed; prior treatment with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) was also allowed." | 1.28 | A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer. ( Hossfeld, DK; Jonat, W; Langenbuch, T; Mross, K, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (6.33) | 18.7374 |
| 1990's | 91 (57.59) | 18.2507 |
| 2000's | 38 (24.05) | 29.6817 |
| 2010's | 19 (12.03) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teepen, JC | 1 |
| van Leeuwen, FE | 1 |
| Tissing, WJ | 1 |
| van Dulmen-den Broeder, E | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| van der Pal, HJ | 1 |
| Loonen, JJ | 1 |
| Bresters, D | 1 |
| Versluys, B | 1 |
| Neggers, SJCMM | 1 |
| Jaspers, MWM | 1 |
| Hauptmann, M | 1 |
| van der Heiden-van der Loo, M | 1 |
| Visser, O | 1 |
| Kremer, LCM | 1 |
| Ronckers, CM | 1 |
| Alkhatib, MH | 1 |
| AlMotwaa, SM | 1 |
| Alkreathy, HM | 1 |
| Moon, SH | 1 |
| Jung, JH | 1 |
| Lee, J | 1 |
| Kim, WW | 1 |
| Park, HY | 1 |
| Lee, JW | 1 |
| Lee, SJ | 1 |
| Singer, A | 1 |
| Tresley, J | 1 |
| Velazquez-Vega, J | 1 |
| Yepes, M | 1 |
| Hsiao, CH | 1 |
| Yeh, KH | 1 |
| Chang, YC | 1 |
| Tsai, CC | 1 |
| McKinnon, E | 1 |
| Xiao, P | 1 |
| Geretti, E | 1 |
| Leonard, SC | 1 |
| Dumont, N | 1 |
| Lee, H | 1 |
| Zheng, J | 1 |
| De Souza, R | 1 |
| Gaddy, DF | 1 |
| Espelin, CW | 1 |
| Jaffray, DA | 1 |
| Moyo, V | 1 |
| Nielsen, UB | 1 |
| Wickham, TJ | 1 |
| Hendriks, BS | 1 |
| Habbel, P | 1 |
| Kurreck, A | 1 |
| Schulz, CO | 1 |
| Regierer, AC | 1 |
| Kaul, D | 1 |
| Scholz, CW | 1 |
| Neumann, C | 1 |
| Possinger, K | 1 |
| Eucker, J | 1 |
| Mituś, JW | 1 |
| Blecharz, P | 1 |
| Walasek, T | 1 |
| Reinfuss, M | 1 |
| Jakubowicz, J | 1 |
| Kulpa, J | 1 |
| Sun, X | 1 |
| Xu, B | 1 |
| Li, Y | 1 |
| Du, J | 1 |
| Dong, L | 1 |
| Gao, X | 1 |
| Li, G | 1 |
| Wei, X | 1 |
| Song, Y | 1 |
| Recchia, F | 2 |
| Candeloro, G | 2 |
| Rosselli, M | 1 |
| Bratta, M | 1 |
| Pasta, V | 1 |
| D'Orazi, V | 1 |
| Fumagalli, LA | 1 |
| Rea, S | 2 |
| Long, JP | 1 |
| Wan, F | 1 |
| Zhang, F | 1 |
| Zhou, J | 1 |
| Don, LF | 1 |
| Di Benedetto, G | 1 |
| Sperti, V | 1 |
| Grassetti, L | 1 |
| Forlini, W | 1 |
| Scalise, A | 1 |
| Bertani, A | 1 |
| Bhatt, L | 1 |
| Fernando, I | 1 |
| Kelly, RJ | 1 |
| Barrett, C | 1 |
| Swan, N | 1 |
| McDermott, R | 1 |
| Knouzy, B | 1 |
| Dubourg, L | 1 |
| Baverel, G | 1 |
| Michoudet, C | 1 |
| Moon, YW | 1 |
| Sohn, JH | 1 |
| Choi, HJ | 1 |
| Chang, H | 1 |
| Park, BW | 1 |
| Kim, SI | 1 |
| Park, S | 1 |
| Koo, JS | 1 |
| Kim, YT | 1 |
| Roh, JK | 1 |
| Chung, HC | 1 |
| Kim, JH | 1 |
| Gatcombe, HG | 1 |
| Olson, TA | 1 |
| Esiashvili, N | 1 |
| Staudacher, L | 1 |
| Cottu, PH | 1 |
| Diéras, V | 1 |
| Vincent-Salomon, A | 1 |
| Guilhaume, MN | 1 |
| Escalup, L | 1 |
| Dorval, T | 1 |
| Beuzeboc, P | 1 |
| Mignot, L | 1 |
| Pierga, JY | 2 |
| Necozione, S | 1 |
| Desideri, G | 1 |
| Recchia, CO | 1 |
| Piazze, J | 1 |
| Sueta, A | 1 |
| Yamamoto, Y | 1 |
| Inoue, K | 1 |
| Kuriwaki, K | 1 |
| Iwase, H | 1 |
| Zils, K | 1 |
| Ebner, F | 1 |
| Ott, M | 1 |
| Müller, J | 1 |
| Baumhoer, D | 1 |
| Greulich, M | 1 |
| Rehnitz, D | 1 |
| Rempen, A | 1 |
| Schaetzle, S | 1 |
| Wilhelm, M | 1 |
| Bielack, S | 1 |
| Schmitt, O | 1 |
| Schubert, C | 1 |
| Feyerabend, T | 2 |
| Hellwig-Bürgel, T | 1 |
| Weiss, C | 3 |
| Kühnel, W | 1 |
| Blot, E | 1 |
| Decaudin, D | 1 |
| Veyradier, A | 1 |
| Bardier, A | 1 |
| Zagame, OL | 1 |
| Pouillart, P | 2 |
| Kellokumpu-Lehtinen, P | 1 |
| Lantto, A | 1 |
| Kokko, R | 1 |
| Elomaa, L | 1 |
| Järvenpää, R | 1 |
| Lehtinen, R | 1 |
| Blomqvist, C | 1 |
| Kosmas, C | 3 |
| Tsavaris, N | 3 |
| Malamos, N | 3 |
| Stavroyianni, N | 1 |
| Gregoriou, A | 1 |
| Rokana, S | 1 |
| Polyzos, A | 3 |
| Zheng, H | 1 |
| Luo, RC | 1 |
| You, CX | 1 |
| Sorio, R | 1 |
| Lombardi, D | 1 |
| Spazzapan, S | 1 |
| La Mura, N | 1 |
| Tabaro, G | 1 |
| Veronesi, A | 1 |
| Schmidt, R | 1 |
| Baumann, F | 1 |
| Knüpfer, H | 1 |
| Brauckhoff, M | 1 |
| Horn, LC | 1 |
| Schönfelder, M | 1 |
| Köhler, U | 1 |
| Preiss, R | 1 |
| De Rosa, L | 1 |
| Anghel, G | 1 |
| Pandolfi, A | 1 |
| Riccardi, M | 1 |
| Amodeo, R | 1 |
| Majolino, I | 1 |
| Dillman, RO | 1 |
| Barth, NM | 1 |
| VanderMolen, LA | 1 |
| Allen, K | 1 |
| Beutel, LD | 1 |
| Chico, S | 1 |
| Esquerdo, G | 1 |
| Llorca, C | 1 |
| Cervera, JM | 1 |
| Briceño, H | 1 |
| Ruiz Tovar, J | 1 |
| Reguero Callejas, ME | 1 |
| Arano Bermejo, JI | 1 |
| Capote Armas, LF | 1 |
| González-Palacios Martínez, F | 1 |
| Cabañas Navarro, L | 1 |
| Nogi, H | 1 |
| Kobayashi, T | 1 |
| Kawase, K | 1 |
| Tabei, I | 1 |
| Toriumi, Y | 1 |
| Suzuki, M | 1 |
| Kawakami, M | 1 |
| Morikawa, T | 1 |
| Uchida, K | 1 |
| Tsakonas, G | 2 |
| Gassiamis, A | 2 |
| Mylonakis, N | 2 |
| Karabelis, A | 2 |
| Skopelitis, H | 1 |
| Morris, CL | 1 |
| Mukundan, S | 1 |
| Heimann, A | 1 |
| Cummings, TJ | 1 |
| Chesnutt, DA | 1 |
| Carter, SK | 1 |
| Hunter, HL | 1 |
| Harrison, EF | 1 |
| Brugger, W | 1 |
| Henschler, R | 1 |
| Heimfeld, S | 1 |
| Berenson, RJ | 1 |
| Mertelsmann, R | 1 |
| Kanz, L | 1 |
| O'Shaughnessy, JA | 2 |
| Cowan, KH | 2 |
| Nienhuis, AW | 3 |
| McDonagh, KT | 1 |
| Sorrentino, BP | 2 |
| Dunbar, CE | 2 |
| Chiang, Y | 1 |
| Wilson, W | 2 |
| Goldspiel, B | 2 |
| Kohler, D | 1 |
| Lind, MJ | 3 |
| Gumbrell, L | 2 |
| Cantwell, BM | 4 |
| Millward, MJ | 5 |
| Simmonds, D | 2 |
| Proctor, M | 2 |
| Chapman, F | 1 |
| McCann, E | 1 |
| Middleton, I | 1 |
| Calvert, AH | 1 |
| Goan, SR | 1 |
| Fichtner, I | 1 |
| Just, U | 1 |
| Karawajew, L | 1 |
| Schultze, W | 1 |
| Krause, KP | 1 |
| von Harsdorf, S | 1 |
| von Schilling, C | 1 |
| Herrmann, F | 1 |
| Meisenberg, BR | 1 |
| Perkins, JB | 7 |
| Fields, KK | 8 |
| Elfenbein, GJ | 7 |
| Boros, L | 3 |
| Garrow, GC | 2 |
| Asbury, RF | 2 |
| Chang, AY | 3 |
| Barrenetxea, G | 1 |
| Schneider, J | 1 |
| Tánago, JG | 1 |
| Pérez, C | 1 |
| Centeno, MM | 1 |
| Rodríguez-Escudero, FJ | 1 |
| Boddy, AV | 2 |
| Idle, JR | 1 |
| Lazarus, HM | 1 |
| Cooper, BW | 1 |
| Creger, RJ | 1 |
| Ballester, OF | 3 |
| Hiemenz, JH | 1 |
| Janssen, WE | 4 |
| Zorsky, PE | 3 |
| Turrill, M | 1 |
| Spicer, DV | 1 |
| Kelley, AS | 1 |
| Herman, RL | 1 |
| Russell, CA | 1 |
| Muggia, FM | 1 |
| Perkins, JP | 1 |
| Hiemenz, JW | 2 |
| Kronish, LE | 2 |
| Machak, MC | 1 |
| Krämer, A | 1 |
| Goldschmidt, H | 4 |
| Hahn, U | 3 |
| Andrassy, K | 1 |
| Millward, M | 2 |
| Lind, M | 1 |
| Robinson, A | 1 |
| Lennard, T | 1 |
| Cantwell, B | 1 |
| Mentzel, M | 3 |
| Wiedemann, G | 2 |
| Mendoza, AS | 1 |
| Stewart, FM | 2 |
| Quesenberry, P | 1 |
| O'Shaughnessy, J | 1 |
| Cowan, K | 1 |
| Cottler-Fox, M | 1 |
| Leitman, S | 1 |
| Goodman, S | 1 |
| Foody, MC | 1 |
| Bryant, G | 2 |
| Gress, R | 1 |
| Dunbar, C | 1 |
| Sorrentino, B | 1 |
| Wiedemann, GJ | 3 |
| Siemens, HJ | 1 |
| Biersack, A | 2 |
| Wössmann, W | 1 |
| Knocks, D | 1 |
| Wagner, T | 3 |
| Quezado, ZM | 1 |
| Wilson, WH | 1 |
| Cunnion, RE | 1 |
| Parker, MM | 1 |
| Reda, D | 1 |
| Ognibene, FP | 1 |
| Perez, JE | 2 |
| Machiavelli, M | 1 |
| Leone, BA | 2 |
| Romero, A | 1 |
| Rabinovich, MG | 1 |
| Vallejo, CT | 2 |
| Bianco, A | 1 |
| Lacava, JA | 2 |
| Rodriguez, R | 2 |
| Cuevas, MA | 2 |
| Ingle, JN | 2 |
| Krook, JE | 1 |
| Mailliard, JA | 1 |
| Hartmann, LC | 1 |
| Wieand, HS | 1 |
| Gurney, H | 2 |
| Harnett, P | 2 |
| Stuart-Harris, R | 1 |
| Kefford, R | 2 |
| Moscinski, LC | 2 |
| Chen, L | 1 |
| Waxman, DJ | 1 |
| Chen, D | 1 |
| Kufe, DW | 1 |
| Trudeau, WL | 1 |
| Overmoyer, BA | 1 |
| Effenbein, GJ | 1 |
| Hui, L | 2 |
| Becher, R | 4 |
| Kloke, O | 4 |
| Hayungs, J | 1 |
| Hartwich, G | 2 |
| Bartels, H | 1 |
| Szanto, J | 2 |
| Wolf, E | 2 |
| Illiger, HJ | 1 |
| Halabi, S | 1 |
| Rieche, K | 1 |
| Hering, KG | 1 |
| Ohl, S | 1 |
| DeDycker, R | 1 |
| Huhn, R | 2 |
| Fischedick, AR | 1 |
| Höfeler, H | 3 |
| Pielken, HJ | 1 |
| Hawig, I | 2 |
| Hirche, H | 2 |
| Seeber, S | 3 |
| Kiraz, S | 1 |
| Baltali, E | 1 |
| Güler, N | 1 |
| Barista, I | 1 |
| Benekli, M | 1 |
| Celik, I | 1 |
| Güllü, IH | 1 |
| Kars, A | 1 |
| Tekuzman, G | 1 |
| Firat, D | 1 |
| Romero, AO | 1 |
| Sabatini, CL | 1 |
| Dominguez, ME | 1 |
| Barbieri, MR | 1 |
| Ortiz, EH | 1 |
| Salvadori, MA | 1 |
| Acuña, LA | 1 |
| Acuña, JM | 1 |
| Langhi, MJ | 1 |
| Amato, S | 1 |
| Machiavelli, MR | 1 |
| Holmes, FA | 2 |
| Mapara, MY | 1 |
| Körner, IJ | 1 |
| Hildebrandt, M | 1 |
| Bargou, R | 1 |
| Krahl, D | 1 |
| Reichardt, P | 1 |
| Dörken, B | 1 |
| Mollenkopf, A | 1 |
| du Bois, A | 1 |
| Meerpohl, HG | 1 |
| Palackdharry, CS | 1 |
| Pronzato, P | 1 |
| Queirolo, P | 1 |
| Landucci, M | 1 |
| Vaira, F | 1 |
| Vigani, A | 1 |
| Gipponi, M | 1 |
| Cafiero, F | 1 |
| Katschinski, DM | 1 |
| Mulkerin, DL | 1 |
| Touhidi, R | 1 |
| Robins, HI | 1 |
| Haas, R | 5 |
| Schmid, H | 3 |
| Hohaus, S | 5 |
| Murea, S | 1 |
| Kaufmann, M | 3 |
| Wannenmacher, M | 1 |
| Wallwiener, D | 4 |
| Bastert, G | 6 |
| Hunstein, W | 1 |
| Bellmunt, J | 2 |
| Eres, N | 1 |
| Ribas, A | 1 |
| Casado, S | 1 |
| Albanell, J | 1 |
| Baselga, J | 1 |
| Malhaire, JP | 1 |
| Labat, JP | 1 |
| Simon, H | 1 |
| Le Maux, H | 1 |
| Spindler, P | 1 |
| Lucas, B | 1 |
| Lamezec, B | 1 |
| Murad, AM | 1 |
| Guimaraes, RC | 1 |
| Amorim, WC | 1 |
| Morici, AC | 1 |
| Ferreira-Filho, AF | 1 |
| Schwartsmann, G | 1 |
| Oblon, DJ | 1 |
| Paul, S | 1 |
| Yankee, R | 1 |
| Bunnell, CA | 1 |
| Thompson, L | 1 |
| Buswell, L | 1 |
| Berkowitz, R | 1 |
| Muto, M | 1 |
| Sheets, E | 1 |
| Shulman, LN | 1 |
| Goldstein, SC | 1 |
| Heimenz, JW | 1 |
| Saez, RA | 1 |
| Sullivan, DM | 1 |
| Partyka, JS | 1 |
| Kronish, LA | 1 |
| Negro, A | 1 |
| Regolisti, G | 1 |
| Perazzoli, F | 1 |
| Davoli, S | 1 |
| Sani, C | 1 |
| Rossi, E | 1 |
| Stobbe, EM | 1 |
| Campisi, C | 2 |
| Fabi, A | 2 |
| Papaldo, P | 2 |
| Tomao, S | 2 |
| Massidda, B | 2 |
| Zappala, A | 2 |
| Ionta, MT | 2 |
| Cognetti, F | 2 |
| Boyages, J | 1 |
| Walters, RS | 1 |
| Valero, V | 2 |
| Esparza-Guerra, L | 1 |
| Hortobagyi, GN | 3 |
| Bitran, JD | 1 |
| Samuels, BL | 1 |
| Marsik, S | 1 |
| Gambino, A | 1 |
| White, L | 1 |
| Lister, J | 1 |
| Rybka, WB | 1 |
| Donnenberg, AD | 1 |
| deMagalhaes-Silverman, M | 1 |
| Pincus, SM | 1 |
| Bloom, EJ | 1 |
| Elder, EM | 1 |
| Ball, ED | 1 |
| Whiteside, TL | 1 |
| Huober, J | 1 |
| Schneeweiss, A | 4 |
| Wittmann, G | 1 |
| Meyer, A | 1 |
| Martin, S | 3 |
| Prince, HM | 4 |
| Gardyn, J | 1 |
| Rischin, D | 3 |
| Francis, P | 3 |
| Gates, P | 2 |
| Chapple, P | 2 |
| Quinn, M | 2 |
| Juneja, S | 2 |
| Wolf, M | 3 |
| Januszewicz, EH | 3 |
| Richardson, G | 3 |
| Scarlett, J | 3 |
| Briggs, P | 3 |
| Brettell, M | 2 |
| Toner, GC | 3 |
| Funk, L | 1 |
| Schlenk, RF | 2 |
| Abdallah, A | 1 |
| Egerer, G | 2 |
| Fersis, N | 1 |
| Kaul, S | 1 |
| Blakey, D | 2 |
| Seymour, JF | 2 |
| Strickland, A | 1 |
| Zalcberg, J | 1 |
| Waller, CF | 1 |
| von Lintig, F | 1 |
| Daskalakis, A | 1 |
| Musahl, V | 1 |
| Lange, W | 1 |
| Klaassen, U | 1 |
| Oberhoff, C | 1 |
| Heckmann, M | 2 |
| Stephan, L | 1 |
| Schnepper, U | 1 |
| Donsbach, GM | 1 |
| Bechtel, C | 1 |
| Rudolph, R | 1 |
| Berke, A | 1 |
| Borquez, D | 1 |
| Schindler, AE | 1 |
| Bearman, S | 1 |
| Vredenburgh, J | 1 |
| Cagnoni, P | 1 |
| Shpall, E | 1 |
| Nieto, Y | 1 |
| Ross, M | 1 |
| Peters, W | 1 |
| Jones, R | 1 |
| Aziz, Z | 2 |
| Rehman, A | 1 |
| Qazi, S | 1 |
| Lobo, F | 1 |
| Frau, A | 1 |
| Barnadas, A | 1 |
| Méndez, M | 1 |
| Lizón, J | 1 |
| Provencio, M | 1 |
| Albistur, JJ | 1 |
| Martínez, P | 1 |
| Sánchez, MJ | 1 |
| Constenla, M | 1 |
| Estévez, LG | 1 |
| Davidson, NG | 1 |
| Davis, AS | 1 |
| Woods, J | 1 |
| Snooks, S | 1 |
| Cheverton, PD | 1 |
| Voso, MT | 1 |
| Asbury, R | 1 |
| Garrow, G | 1 |
| Rubins, J | 1 |
| Palangié, T | 1 |
| Blohmer, JU | 1 |
| Paepke, S | 1 |
| Kissner, L | 1 |
| Elling, D | 1 |
| Fleige, B | 1 |
| Grineisen, Y | 1 |
| Lichtenegger, W | 1 |
| Seker, H | 1 |
| Bertram, B | 1 |
| Bürkle, A | 1 |
| Kaina, B | 1 |
| Pohl, J | 1 |
| Koepsell, H | 1 |
| Wiesser, M | 1 |
| Schilling, EM | 1 |
| Stückle, CA | 1 |
| Kirchner, J | 1 |
| Donnerstag, F | 1 |
| Liermann, D | 1 |
| Börner, K | 1 |
| Kisro, J | 1 |
| Brüggemann, SK | 1 |
| Hagenah, W | 1 |
| Peters, SO | 1 |
| Ricotti, L | 1 |
| Barzanti, F | 1 |
| Tesei, A | 1 |
| Amadori, D | 1 |
| Gasperi-Campani, A | 1 |
| Frassineti, GL | 1 |
| Zoli, W | 1 |
| Arends, J | 1 |
| Hill, PA | 1 |
| Power, DA | 1 |
| Johnstone, EC | 1 |
| Griffin, MJ | 1 |
| Hensel, M | 1 |
| Goerner, R | 1 |
| Khbeis, T | 1 |
| Solomayer, E | 1 |
| Grischke, EM | 2 |
| Ho, AD | 1 |
| Miglietta, L | 1 |
| Marenghi, C | 1 |
| Nizzo, R | 1 |
| Foglia, G | 1 |
| Ragni, N | 1 |
| Boccardo, F | 1 |
| Jäger, B | 1 |
| Vesely, H | 1 |
| Mahlmann, B | 1 |
| Richter, E | 1 |
| Sreerama, L | 1 |
| Sládek, NE | 1 |
| Pérez-Calvo, J | 2 |
| Martínez-Aguillo, M | 2 |
| García-Rayo, S | 2 |
| Ramón y Cajal, T | 1 |
| Santisteban, M | 1 |
| Ordóñez, JM | 1 |
| Inogés, S | 1 |
| Subirá, ML | 1 |
| Martín-Algarra, S | 2 |
| Brugarolas, A | 2 |
| Martínez-Monge, R | 1 |
| Fernández-Hidalgo, O | 1 |
| Subirá, L | 1 |
| Rebollo, J | 1 |
| Azinovic, I | 1 |
| Sana, S | 1 |
| Akram, M | 1 |
| Ilyas, N | 1 |
| Seo, JH | 1 |
| Whang, YM | 1 |
| Kim, BS | 1 |
| Choi, CW | 1 |
| Shin, SW | 1 |
| Kim, YH | 1 |
| Kim, JS | 1 |
| Goo, BH | 1 |
| Bashford, J | 1 |
| Wall, D | 1 |
| Parker, N | 1 |
| Haylock, D | 1 |
| Simmons, P | 1 |
| Hempel, P | 1 |
| Müller, P | 1 |
| Oruzio, D | 1 |
| Behr, W | 1 |
| Brockmeyer, C | 1 |
| Wochner, M | 1 |
| Ehnle, S | 1 |
| Riethmüller, R | 1 |
| Schlimok, G | 1 |
| Khan, SA | 1 |
| Badve, S | 1 |
| Trent II, JC | 1 |
| Benjamin, RS | 1 |
| Buzdar, AU | 1 |
| Legha, SS | 1 |
| Tashima, CK | 1 |
| Yap, HY | 1 |
| Hersh, EM | 1 |
| Blumenschein, GR | 1 |
| Bodey, GP | 1 |
| Schnitker, J | 1 |
| Brock, N | 1 |
| Burkert, H | 1 |
| Fichtner, E | 1 |
| Ahmann, DL | 2 |
| Bisel, HF | 2 |
| Hahn, RG | 2 |
| Eagan, RT | 1 |
| Edmonson, JH | 2 |
| Steinfeld, JL | 1 |
| Tormey, DC | 1 |
| Taylor, WF | 1 |
| Hawkins, RE | 1 |
| Schofield, JB | 1 |
| Wiltshaw, E | 1 |
| Fisher, C | 1 |
| McKinna, JA | 1 |
| Brun, B | 1 |
| Nasr, E | 1 |
| Randria, G | 1 |
| Feuilhade, F | 1 |
| Gimonet, JF | 1 |
| Le Bourgeois, JP | 1 |
| Gad-el-Mawla, N | 2 |
| Hennessy, C | 2 |
| Sawan, A | 1 |
| Dawes, PJ | 1 |
| Lennard, TW | 2 |
| Lange, OF | 2 |
| Scheef, W | 2 |
| Haase, KD | 2 |
| Leyendecker, R | 1 |
| Urban, G | 1 |
| Zegners, G | 1 |
| Roszinski, S | 1 |
| May, D | 1 |
| Wandl, U | 2 |
| Niederle, N | 1 |
| Richter, R | 1 |
| Scheulen, ME | 1 |
| Schmidt, CG | 2 |
| Harris, AL | 1 |
| Paridaens, R | 2 |
| Focan, C | 1 |
| Michel, J | 1 |
| Piccart, M | 2 |
| Salamon, E | 1 |
| Beauduin, M | 1 |
| Closon, MT | 1 |
| Tueni, E | 1 |
| Vindevoghel, A | 1 |
| Majois, F | 1 |
| Manegold, C | 1 |
| Worst, P | 1 |
| Bickel, J | 1 |
| Drings, P | 1 |
| Sanchiz, F | 1 |
| Milla, A | 1 |
| Funahashi, H | 1 |
| Sato, Y | 1 |
| Imai, T | 1 |
| Kato, N | 1 |
| Ando, K | 1 |
| Oike, E | 1 |
| Odaka, K | 1 |
| Ono, M | 1 |
| Narita, T | 1 |
| Kato, M | 1 |
| Franzen, D | 1 |
| Pöhler, E | 1 |
| Hilger, HH | 1 |
| Richard, V | 1 |
| Sculier, JP | 1 |
| Ghavamzadeh, A | 1 |
| Hoffmann, W | 1 |
| Weidmann, B | 1 |
| Migeod, F | 1 |
| Könner, J | 1 |
| Morales, S | 1 |
| Navarro, M | 1 |
| Solé, LA | 1 |
| Hamza, MR | 1 |
| Zikri, ZK | 1 |
| Elserafi, M | 1 |
| el-Khodari, A | 1 |
| Khaled, H | 1 |
| Gafaar, R | 1 |
| Langenbuch, T | 1 |
| Mross, K | 1 |
| Jonat, W | 1 |
| Hossfeld, DK | 1 |
| Kurschel, E | 1 |
| Schilcher, RB | 1 |
| Weinhardt, O | 1 |
| Steger, GG | 1 |
| Dittrich, C | 1 |
| Schlappack, O | 1 |
| Mader, R | 1 |
| Herold, C | 1 |
| Brade, WP | 2 |
| Keller, A | 1 |
| Moser, K | 1 |
| Zalupski, M | 1 |
| Baker, LH | 1 |
| Schaid, DJ | 1 |
| Herdrich, K | 1 |
| Varini, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Breast Sarcomas: A Retrospective Analysis of Clinical Features and Outcomes[NCT04749446] | 300 participants (Anticipated) | Observational | 2021-04-02 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for ifosfamide and Breast Cancer
| Article | Year |
|---|---|
Unusual aggressive breast cancer: metastatic malignant phyllodes tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidi | 2013 |
Metaplastic carcinoma of the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemoradiotherapy; Etoposi | 2015 |
[Primary breast diffuse large B-cell lymphoma-report of 21 cases from China with literatures review].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2015 |
Ifosfamide in advanced/disseminated breast cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2003 |
Glufosfamide: beta-D-Glc-IPM, D 19575.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Clinical Trials as Topic; Female; Glucose; Huma | 2005 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
The anticancer spectrum of ifosfamide.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Lung Neoplasms; Mal | 1982 |
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cycl | 1995 |
Ifosfamide in the treatment of breast cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1996 |
Paclitaxel combination therapy in the treatment of metastatic breast cancer.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1996 |
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as To | 1998 |
Phyllodes tumors of the breast.
Topics: Antineoplastic Agents; Breast Neoplasms; Cisplatin; Disease-Free Survival; Doxorubicin; Etoposide; F | 2001 |
Primary soft tissue sarcoma of the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorub | 2001 |
Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes.
Topics: Adult; Breast Neoplasms; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Phyllo | 1992 |
Use of ifosfamide in the management of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; | 1992 |
Activity of ifosfamide in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Ifosfamide | 1992 |
Ifosfamide.
Topics: Breast Neoplasms; Drug Evaluation, Preclinical; Female; Humans; Ifosfamide; Lung Neoplasms; Lymphoma | 1988 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
59 trials available for ifosfamide and Breast Cancer
| Article | Year |
|---|---|
Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docet | 2003 |
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carbo | 2005 |
Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Respo | 2007 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Ble | 1994 |
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedul | 1995 |
Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbo | 1995 |
Phase I study of escalating doses of paclitaxel (Taxol) with fixed doses of ifosfamide, carboplatin, and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinom | 1995 |
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1995 |
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.
Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1995 |
Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1993 |
Results of chemotherapy using ifosfamide with doxorubicin in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; | 1994 |
Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1993 |
Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant (ABMT) with neoR-transduced bone marrow and peripheral blood stem cells in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Cispl | 1993 |
High-dose ifosfamide is associated with severe, reversible cardiac dysfunction.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Bone | 1993 |
Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Drug Admin | 1993 |
Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cystitis; Drug Administration Schedule; D | 1995 |
Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Hemoglo | 1995 |
Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 1996 |
Epirubicin and ifosfamide in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; | 1996 |
Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; H | 1996 |
Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ifosf | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carci | 1997 |
Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1997 |
Optimization of chemotherapy administration for clinical 41.8 degrees C whole body hyperthermia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Temperature; Breast Neoplasms; Carboplatin; Car | 1997 |
Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, | 1997 |
Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; F | 1997 |
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Fe | 1998 |
Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1998 |
Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Female; Humans; Ifosfamide; Mesna; | 1998 |
A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin | 1995 |
Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Topics: Adoptive Transfer; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Busulfan; Cells, Cultured; | 1995 |
Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Fe | 1998 |
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Combined | 1999 |
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Combined Modalit | 1999 |
Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 1999 |
Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1999 |
Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1999 |
Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; | 1999 |
Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1999 |
FILM (5-fluorouracil, ifosfamide, leucovorin and mitomycin C), an alternative chemotherapy regimen suitable for the treatment of advanced breast cancer in the 'out-patient' setting.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Brea | 1999 |
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, | 1999 |
Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Res | 1999 |
Dose-intense salvage therapy after neoadjuvant chemotherapy: feasibility and preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, | 1999 |
Dose- intensified, preoperative and adjuvant chemotherapy in patients with T3- and T4- breast cancer: toxicity, clinical and pathological remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1999 |
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2001 |
Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2001 |
Factors determining the actual received dose intensity in a program of multicyclic dose-intensive alternating chemotherapy with sequential stem cell support.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; | 2001 |
Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 2001 |
Phase 1 trial of ifosfamide and adriamycin in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans | 2001 |
A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Pro | 2002 |
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Mo | 2002 |
Combination of high-dose chemotherapy and monoclonal antibody in breast-cancer patients: a pilot trial to monitor treatment effects on disseminated tumor cells.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast N | 2000 |
Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination | 1979 |
Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Breast Neoplasms; Child; Clinical Trials as Topic; Cyclopho | 1976 |
Palliative chemo-radiotherapy with ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer. Results of a prospective multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1990 |
The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1987 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
83 other studies available for ifosfamide and Breast Cancer
| Article | Year |
|---|---|
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla | 2017 |
Incorporation of ifosfamide into various essential oils -based nanoemulsions ameliorates its apoptotic effect in the cancers cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Compounding | 2019 |
Complete remission of giant malignant phyllodes tumor with lung metastasis: A case report.
Topics: Antineoplastic Agents; Axilla; Breast Neoplasms; Doxorubicin; Female; Humans; Ifosfamide; Lung Neopl | 2019 |
High-dose tamoxifen plus ifosfamide and anthracycline in a patient with angiosarcoma of the breast.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatal Outcome; Fem | 2013 |
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamid | 2015 |
Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 2015 |
Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neopla | 2016 |
Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
DTC chemotherapy regimen is associated with higher incidence of premature ovarian failure in women of reproductive age with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel | 2016 |
Temporary remission of a multirecurrent cystosarcoma phyllodes of the breast by using continuous chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Ifos | 2009 |
Primary squamous cell carcinoma of the breast: achieving long-term control with cisplatin-based chemotherapy.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modalit | 2009 |
Metastatic phyllodes tumor causing small-bowel obstruction.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Combined Modality | 2009 |
Ifosfamide metabolite chloroacetaldehyde inhibits cell proliferation and glucose metabolism without decreasing cellular ATP content in human breast cancer cells MCF-7.
Topics: Acetaldehyde; Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brea | 2010 |
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docet | 2010 |
Metastatic primary angiosarcoma of the breast in a pediatric patient with a complete response to systemic chemotherapy and definitive radiation therapy: case report and review of the literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combin | 2010 |
Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplati | 2011 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; C | 2011 |
Stromal sarcoma of the breast with lung metastases showing a clinical complete response to doxorubicin plus ifosfamide treatment: report of a case.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Female; Humans; Ifosfamide; Lung Neopla | 2011 |
Extraskeletal osteosarcoma of the breast in an adolescent girl.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemot | 2012 |
Preferential topography of proteins regulating vascularization and apoptosis in a MX1 xenotransplant after treatment with hypoxia, hyperthermia, ifosfamide, and irradiation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Cell Adhesion Molecules; Co | 2002 |
Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency.
Topics: ADAM Proteins; ADAMTS13 Protein; Adenocarcinoma; Anemia, Hemolytic; Antineoplastic Combined Chemothe | 2002 |
Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2002 |
[Clinical observation of the efficacy of navelbine combined with ifosfamide and cisplatin in the treatment of advanced breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Humans; | 2003 |
CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases; Breast Ne | 2004 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2004 |
A rare case of breast sarcoma brain metastases.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Fatal Outcome; Female; Humans; Ifos | 2005 |
Malignant mixed Mullerian tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemo | 2006 |
Primary rhabdomyosarcoma of the breast in a 13-year-old girl: report of a case.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Dactin | 2007 |
Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; D | 2008 |
Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, | 1994 |
The severe combined immunodeficient-human peripheral blood stem cell (SCID-huPBSC) mouse: a xenotransplant model for huPBSC-initiated hematopoiesis.
Topics: Adult; Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone | 1995 |
High-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Etoposide; Hematopoie | 1995 |
Angiosarcoma of the breast and pregnancy: a new therapeutic approach.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dactinomycin; Female; Heman | 1995 |
Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Half-Life; Humans; | 1995 |
Progressive renal failure in two breast cancer patients after high-dose ifosfamide.
Topics: Adult; Breast Neoplasms; Female; Humans; Ifosfamide; Kidney Failure, Chronic; Middle Aged | 1994 |
The effect of ifosfamide on tumor oxygenation at different temperatures.
Topics: Animals; Breast Neoplasms; Female; Humans; Hydrogen-Ion Concentration; Ifosfamide; Lactates; Lactic | 1994 |
Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neo | 1993 |
Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide.
Topics: Animals; Body Temperature; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Ifosf | 1993 |
Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Body Weight; Breast Neoplasms; Cell Cycle; | 1996 |
Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Marrow Transplant | 1996 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen | 1996 |
Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neo | 1997 |
[Sequential course and prospective management of ifosfamide-induced multi-organ toxicity].
Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modal | 1996 |
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; D | 1997 |
One case of Stewart-Treves syndrome successfully treated at two years by chemotherapy and radiation therapy in a 73-year-old woman.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic | 1997 |
Allogeneic transplantation after a conditioning regimen with ifosfamide, carboplatin and etoposide (ICE).
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carboplatin; Etoposide; Female; Hematopoietic S | 1997 |
Ifosfamide-induced renal Fanconi syndrome with associated nephrogenic diabetes insipidus in an adult patient.
Topics: Adult; Antineoplastic Agents, Alkylating; Breast Neoplasms; Diabetes Insipidus, Nephrogenic; Electro | 1998 |
Effects of a combined thermochemotherapy on the xenotransplanted human mammary carcinoma MX-1. A light and transmission electron microscopic study.
Topics: Animals; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Ifosfam | 1998 |
Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality | 1998 |
Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness.
Topics: Adult; Antineoplastic Agents, Alkylating; Breast Neoplasms; Child; Clinical Trials as Topic; Cycloph | 1998 |
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carb | 1999 |
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Ci | 1999 |
Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent.
Topics: Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; CHO Cells; Cricetinae; DNA Damage; DNA | 2000 |
[Computerized tomography detection of portal vein air accumulation in severe gastroenteritis during chemotherapy].
Topics: Adult; Antineoplastic Agents, Alkylating; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modalit | 2000 |
Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Topics: Acetaldehyde; Animals; Antineoplastic Agents, Alkylating; Breast Neoplasms; Humans; Ifosfamide; Mice | 2000 |
Combined 4-hydroxy-ifosfamide and vinorelbine treatment in established and primary human breast cell cultures.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; | 2000 |
Effects of a combined thermochemotherapy on markers of apoptosis, differentiation and adhesion in the human mammary carcinoma MX-1. A light microscopic and immunohistochemical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Biomarkers; Breas | 2000 |
Tubulointerstitial nephritis following high-dose ifosfamide in three breast cancer patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Ductal, Breast; Contraindicat | 2000 |
Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, | 2000 |
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Dose-Response | 2001 |
Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents, Alkylating; Biomarke | 2001 |
An analysis of a multiple-drug program in the treatment of patients with advanced breast cancer utilizing 5-fluorouracil, cyclophosphamide, and prednisone with or without vincristine.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Breast Neoplasms; Cyclophosphamide; Doxorubic | 1975 |
[Pilot study of chemotherapy with mitoxantrone, ifosfamide, 5-fluorouracil in metastatic cancers of the breast. Preliminary study].
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cause of Death; Fe | 1991 |
Primary tumour mutant p53 gene protein and epidermal growth factor receptor expression and doxorubicin plus ifosfamide for recurrent breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; ErbB Receptors | 1992 |
Epidermal growth factor receptors and doxorubicin plus ifosfamide/mesna in recurrent breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; ErbB Receptors | 1991 |
Palliative radio-chemotherapy with ifosfamide and BCNU for breast cancer patients with cerebral metastases. A 5-year experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carm | 1990 |
Local hyperthermia enhances cyclophosphamide, ifosfamide and cis-diamminedichloroplatinum cytotoxicity on human-derived breast carcinoma and sarcoma xenografts in nude mice.
Topics: Animals; Body Temperature; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; | 1992 |
Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1991 |
Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Eva | 1990 |
Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ifosfamide; | 1990 |
Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female; Hu | 1990 |
High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema | 1990 |
[Clinical efficacy of ifosfamide for liver metastasis of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Breast Neoplasms; Doxorubicin; Drug Ad | 1990 |
[Pneumo- and cardiotoxic side effects following combination chemotherapy with epirubicin and ifosfamide].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Non | 1990 |
Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anuria; Breast Neoplasms; Dose-Response Relationship | 1990 |
Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; F | 1990 |
Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Epirubicin; Femal | 1990 |
Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; | 1990 |
Ifosfamide combination chemotherapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ifosfamide | 1990 |
Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Female; Fl | 1990 |
A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Epir | 1990 |
Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1989 |
Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ifosf | 1988 |